blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2931298

EP2931298 - FUSION OF HUMAN GROWTH HORMONE AND ALBUMIN, FORMULATION AND USES THEREOF [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  30.06.2017
Database last updated on 22.08.2024
FormerRequest for examination was made
Status updated on  12.02.2017
Most recent event   Tooltip30.06.2017Application deemed to be withdrawnpublished on 02.08.2017  [2017/31]
Applicant(s)For all designated states
Teva Pharmaceutical Industries Ltd.
5 Basel Street
P.O. Box 3190
49131 Petah Tiqva / IL
[N/P]
Former [2015/43]For all designated states
Teva Pharmaceutical Industries Ltd.
5 Basel Street P.O. Box 3190
49131 Petah Tiqva / IL
Inventor(s)01 / BROWN, Kurt
634 Moreno Road
Narberth, PA 19072 / US
02 / BASSAN, Merav
15a Ziporen Street
Netanya / IL
 [2015/43]
Representative(s)D Young & Co LLP
3 Noble Street
London EC2V 7BQ / GB
[N/P]
Former [2015/43]D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Application number, filing date13861675.010.12.2013
[2015/43]
WO2013US74145
Priority number, dateUS201261736267P12.12.2012         Original published format: US 201261736267 P
[2015/43]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014093354
Date:19.06.2014
Language:EN
[2014/25]
Type: A1 Application with search report 
No.:EP2931298
Date:21.10.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 19.06.2014 takes the place of the publication of the European patent application.
[2015/43]
Search report(s)International search report - published on:US19.06.2014
(Supplementary) European search report - dispatched on:EP08.06.2016
ClassificationIPC:A61K38/00, C12P21/04, A61P5/02
[2016/27]
CPC:
A61K38/27 (EP,US); A61P5/02 (EP); A61P5/06 (EP)
C-Set:
A61K38/27, A61K2300/00 (EP,US)
Former IPC [2015/43]A61K38/00, C12P21/04
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/43]
Extension statesBA09.07.2015
ME09.07.2015
TitleGerman:FUSION VON MENSCHLICHEN WACHSTUMSHORMONEN UND ALBUMIN SOWIE FORMULIERUNG DARAUS UND VERWENDUNG DAVON[2015/43]
English:FUSION OF HUMAN GROWTH HORMONE AND ALBUMIN, FORMULATION AND USES THEREOF[2015/43]
French:FUSION D'HORMONE DE CROISSANCE HUMAINE ET D'ALBUMINE, SA FORMULATION ET SES UTILISATIONS[2015/43]
Entry into regional phase09.07.2015National basic fee paid 
09.07.2015Search fee paid 
09.07.2015Designation fee(s) paid 
09.07.2015Examination fee paid 
Examination procedure09.07.2015Amendment by applicant (claims and/or description)
09.07.2015Examination requested  [2015/43]
05.01.2017Application deemed to be withdrawn, date of legal effect  [2017/31]
13.02.2017Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2017/31]
Fees paidRenewal fee
22.12.2015Renewal fee patent year 03
Penalty fee
Additional fee for renewal fee
31.12.201604   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]US2002155990  (FOSTER MICHAEL B [US]) [A] 15 * the whole document *;
 [A]US2002156019  (FOSTER MICHAEL B [US]) [A] 15 * the whole document *;
 [Y]WO03060071  (HUMAN GENOME SCIENCES INC [US], et al) [Y] 15 * page 5, paragraph 7 * * page 455, paragraph 1238 - page 461, paragraph 1262 * * paragraph [0251] *;
 [Y]WO2011029892  (HOFFMANN LA ROCHE [CH], et al) [Y] 15 * page 1, paragraph 26; claim 7 *;
 [Y]  - WILCOX ANGELA M, "Characterization of albutropin fusion protein: A novel, long-acting form of human growth hormone", AMERICAN CHEMICAL SOCIETY. ABSTRACTS OF PAPERS (AT THE NATIONAL MEETING), AMERICAN CHEMICAL SOCIETY, US, (20030101), vol. 225, no. 1-2, ISSN 0065-7727, page BIOT10, XP009157330 [Y] 15 * the whole document *
 [Y]  - OSBORN B L ET AL, "Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, (20021205), vol. 456, no. 1-3, doi:10.1016/S0014-2999(02)02644-4, ISSN 0014-2999, pages 149 - 158, XP002339364 [Y] 15 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0014-2999(02)02644-4
 [Y]  - Eva Y Chi, "Excipients and their Effects on the Quality of Biologics", (20120414), pages 1 - 9, URL: https://www.aaps.org/uploadedFiles/Content/Sections_and_Groups/Sections/Formulation_Design_And_Development_Section/FDDTechCornerMay2012.pdf, (20160519), XP002757831 [Y] 15 * page 3, paragraph 4 *
 [A]  - "CONSENSUS GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF ADULTS WITHGROWTH HORMONE DEFICIENCY: SUMMARY STATEMENT OF THE GROWTH HORMONE RESEARCH SOCIETY WORKSHOP ON ADULT GROWTH HORMONE DEFICIENCY", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, THE ENDOCRINE SOCIETY, US, (19880201), vol. 83, no. 2, doi:10.1210/JC.83.2.379, ISSN 0021-972X, pages 379 - 381, XP000990269 [A] 15 * the whole document *

DOI:   http://dx.doi.org/10.1210/jc.83.2.379
 [T]  - ORIT COHEN-BARAK ET AL, "Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency", EUROPEAN JOURNAL OF ENDOCRINOLOGY, GB, (20151128), vol. 173, no. 5, doi:10.1530/EJE-15-0554, ISSN 0804-4643, pages 541 - 551, XP055273213 [T] 15

DOI:   http://dx.doi.org/10.1530/EJE-15-0554
International search[Y]WO2011029892  (HOFFMANN LA ROCHE [CH], et al);
 [Y]US8108149  (CLARK ROSS GRAHAM [NZ], et al);
 [X]US8211439  (ROSEN CRAIG A [US], et al);
 [Y]  - KEMP, SF ET AL., "Pharmacokinetic And Pharmacodynamic Characteristics Of A Long-Acting Growth Hormone Preparation (Nutrpin Depot) In GH-Deficient Children.", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, (20040701), vol. 89, no. 7, pages 3234 - 3240, XP055185639

DOI:   http://dx.doi.org/10.1210/jc.2003-030825
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.